A. López Alfonso , B. Martínez-Amores , N. Herradón , R. Molina Villaverde
{"title":"胰腺癌更新","authors":"A. López Alfonso , B. Martínez-Amores , N. Herradón , R. Molina Villaverde","doi":"10.1016/j.med.2025.01.013","DOIUrl":null,"url":null,"abstract":"<div><div>Exocrine pancreatic cancer is a highly lethal malignant neoplasm. It is the fourth leading cause of death due to cancer in developed countries and, given the gradual increase in incidence, it is expected to become the second leading cause of death due to cancer in the coming years. Surgical resection is the only curative treatment. Since the disease detected in advanced stages in most patients, few will be candidates for a pancreatectomy. Despite this, only 10% of patients will potentially be cured, due to the poor prognosis of this disease and the high proportion of relapses. New treatments have been added in recent years to the small therapeutic arsenal for this disease, which has led to longer survival times. More research is needed to improve this disease's grim prognosis.</div></div>","PeriodicalId":100912,"journal":{"name":"Medicine - Programa de Formación Médica Continuada Acreditado","volume":"14 25","pages":"Pages 1486-1494"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Actualización del cáncer de páncreas\",\"authors\":\"A. López Alfonso , B. Martínez-Amores , N. Herradón , R. Molina Villaverde\",\"doi\":\"10.1016/j.med.2025.01.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Exocrine pancreatic cancer is a highly lethal malignant neoplasm. It is the fourth leading cause of death due to cancer in developed countries and, given the gradual increase in incidence, it is expected to become the second leading cause of death due to cancer in the coming years. Surgical resection is the only curative treatment. Since the disease detected in advanced stages in most patients, few will be candidates for a pancreatectomy. Despite this, only 10% of patients will potentially be cured, due to the poor prognosis of this disease and the high proportion of relapses. New treatments have been added in recent years to the small therapeutic arsenal for this disease, which has led to longer survival times. More research is needed to improve this disease's grim prognosis.</div></div>\",\"PeriodicalId\":100912,\"journal\":{\"name\":\"Medicine - Programa de Formación Médica Continuada Acreditado\",\"volume\":\"14 25\",\"pages\":\"Pages 1486-1494\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicine - Programa de Formación Médica Continuada Acreditado\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304541225000186\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine - Programa de Formación Médica Continuada Acreditado","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304541225000186","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Exocrine pancreatic cancer is a highly lethal malignant neoplasm. It is the fourth leading cause of death due to cancer in developed countries and, given the gradual increase in incidence, it is expected to become the second leading cause of death due to cancer in the coming years. Surgical resection is the only curative treatment. Since the disease detected in advanced stages in most patients, few will be candidates for a pancreatectomy. Despite this, only 10% of patients will potentially be cured, due to the poor prognosis of this disease and the high proportion of relapses. New treatments have been added in recent years to the small therapeutic arsenal for this disease, which has led to longer survival times. More research is needed to improve this disease's grim prognosis.